Implementation to Impact (i2i), School of Population Health, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Hereditary Cancer Centre, Prince of Wales Hospital, Randwick, New South Wales, Australia.
J Genet Couns. 2024 Oct;33(5):973-984. doi: 10.1002/jgc4.1803. Epub 2023 Oct 21.
In the genomic era, the availability of gene panel and whole genome/exome sequencing is rapidly increasing. Opportunities for providing former patients with new genetic information are also increasing over time and recontacting former patients with new information is likely to become more common. Breast cancer Refined Analysis of Sequence Tests-Risk And Penetrance (BRA-STRAP) is an Australian study of individuals who had previously undertaken BRCA1 and BRCA2 genetic testing, with no pathogenic variants detected. Using a waiver of consent, stored DNA samples were retested using a breast/ovarian cancer gene panel and clinically significant results returned to the patient (or next of kin, if deceased). This qualitative study aimed to explore patient experiences, opinions, and expectations of recontacting in the Australian hereditary cancer setting. Participants were familial cancer clinic patients (or next of kin) who were notified of a new pathogenic variant identified via BRA-STRAP. In-depth, semi-structured interviews were conducted approximately 6 weeks post-result. Interviews were transcribed verbatim and analyzed using an inductive thematic approach. Thirty participants (all female; average age = 57; range 36-84) were interviewed. Twenty-five were probands, and five were next of kin. Most women reported initial shock upon being recontacted with unexpected news, after having obtained a sense of closure related to their initial genetic testing experiences and cancer diagnosis. For most, this initial distress was short-lived, followed by a process of readjustment, meaning-making and adaptation that was facilitated by perceived clinical and personal utility of the information. Women were overall satisfied with the waiver of consent approach and recontacting process. Results are in line with previous studies suggesting that patients have positive attitudes about recontacting. Women in this study valued new genetic information gained from retesting and were satisfied with the BRA-STRAP recontact model. Practice implications to facilitate readjustment and promote psychosocial adaptation were identified.
在基因组时代,基因面板和全基因组/外显子测序的可用性正在迅速增加。随着时间的推移,为以前的患者提供新遗传信息的机会也在增加,重新联系以前的患者并提供新信息可能会变得更加普遍。澳大利亚的乳腺癌精细序列测试风险和外显率(BRA-STRAP)研究是对以前进行过 BRCA1 和 BRCA2 基因检测但未发现致病性变异的个体进行的研究。该研究使用同意豁免,使用乳腺癌/卵巢癌基因面板重新测试存储的 DNA 样本,并将临床意义重大的结果返回给患者(或已故患者的近亲)。这项定性研究旨在探讨在澳大利亚遗传性癌症环境中重新联系患者的经历、意见和期望。参与者为家族性癌症诊所的患者(或近亲),他们通过 BRA-STRAP 得知了新的致病性变异。在获得结果后大约 6 周,进行了深入的半结构化访谈。访谈内容逐字转录,并使用归纳主题方法进行分析。共采访了 30 名参与者(均为女性;平均年龄 57 岁;范围 36-84 岁)。25 名是先证者,5 名是近亲。大多数女性在获得最初的基因检测结果和癌症诊断时,报告说在被重新联系并得知意想不到的消息时最初感到震惊,之后感到安心。对大多数人来说,这种最初的痛苦是短暂的,随后是一个重新调整、寻找意义和适应的过程,这得益于对信息的临床和个人效用的认识。女性对同意豁免和重新联系过程总体感到满意。研究结果与之前的研究一致,表明患者对重新联系持积极态度。这项研究中的女性重视从重新测试中获得的新遗传信息,对 BRA-STRAP 重新联系模式感到满意。确定了促进重新调整和促进心理社会适应的实践意义。